Nektar Therapeutics (NASDAQ:NKTR) has been given a $125.00 target price by research analysts at HC Wainwright in a research report issued on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 33.16% from the company’s previous close.
Several other brokerages have also recently issued reports on NKTR. BidaskClub upgraded Nektar Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, March 21st. Mizuho set a $89.00 price target on Nektar Therapeutics and gave the company a “buy” rating in a research report on Thursday, March 29th. Cowen restated a “buy” rating and issued a $101.00 price target on shares of Nektar Therapeutics in a research report on Friday, March 2nd. Jefferies Group boosted their price target on Nektar Therapeutics to $103.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. Finally, Canaccord Genuity boosted their price target on Nektar Therapeutics to $94.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $63.75.
NKTR opened at $93.87 on Monday. The company has a debt-to-equity ratio of 2.79, a quick ratio of 5.63 and a current ratio of 5.82. Nektar Therapeutics has a one year low of $17.33 and a one year high of $111.36. The stock has a market cap of $15,105.83, a PE ratio of -170.67 and a beta of 1.73.
Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.14. Nektar Therapeutics had a negative return on equity of 156.85% and a negative net margin of 31.42%. The business had revenue of $95.47 million for the quarter, compared to analysts’ expectations of $36.96 million. During the same quarter in the previous year, the firm earned ($0.28) earnings per share. The business’s revenue was up 154.9% compared to the same quarter last year. equities research analysts anticipate that Nektar Therapeutics will post -1.33 EPS for the current year.
In other Nektar Therapeutics news, SVP Stephen K. Doberstein sold 2,426 shares of Nektar Therapeutics stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $82.94, for a total value of $201,212.44. Following the sale, the senior vice president now owns 67,394 shares of the company’s stock, valued at approximately $5,589,658.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher A. Kuebler sold 40,000 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $97.60, for a total value of $3,904,000.00. Following the completion of the sale, the director now directly owns 43,100 shares in the company, valued at approximately $4,206,560. The disclosure for this sale can be found here. Insiders sold a total of 369,592 shares of company stock worth $34,241,981 in the last ninety days. 5.44% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. California Public Employees Retirement System boosted its holdings in Nektar Therapeutics by 2.3% in the 3rd quarter. California Public Employees Retirement System now owns 195,200 shares of the biopharmaceutical company’s stock valued at $4,685,000 after purchasing an additional 4,300 shares in the last quarter. Advisor Partners LLC purchased a new stake in shares of Nektar Therapeutics during the 4th quarter worth approximately $393,000. Carillon Tower Advisers Inc. purchased a new stake in shares of Nektar Therapeutics during the 4th quarter worth approximately $43,024,000. Aperio Group LLC boosted its stake in shares of Nektar Therapeutics by 14.6% during the 4th quarter. Aperio Group LLC now owns 49,830 shares of the biopharmaceutical company’s stock worth $2,976,000 after acquiring an additional 6,345 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in shares of Nektar Therapeutics by 38.0% during the 4th quarter. Teachers Advisors LLC now owns 930,424 shares of the biopharmaceutical company’s stock worth $55,565,000 after acquiring an additional 256,078 shares in the last quarter. 96.22% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/09/hc-wainwright-analysts-give-nektar-therapeutics-nktr-a-125-00-price-target.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.